Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Gross Margin (2016 - 2019)

Plus Therapeutics has reported Gross Margin over the past 9 years, most recently at 83.78% for Q1 2019.

  • Quarterly Gross Margin rose 6299.0% to 83.78% in Q1 2019 from the year-ago period, while the trailing twelve-month figure was 61.05% through Mar 2019, up 4610.0% year-over-year, with the annual reading at 82.48% for FY2018, 7705.0% up from the prior year.
  • Gross Margin was 83.78% for Q1 2019 at Plus Therapeutics, down from 96.69% in the prior quarter.
  • Over five years, Gross Margin peaked at 96.69% in Q4 2018 and troughed at 21.15% in Q1 2017.
  • The 5-year median for Gross Margin is 27.04% (2017), against an average of 31.31%.
  • Year-over-year, Gross Margin crashed -7861bps in 2017 and then surged 9231bps in 2018.
  • A 5-year view of Gross Margin shows it stood at 49.16% in 2015, then decreased by -28bps to 35.54% in 2016, then plummeted by -88bps to 4.38% in 2017, then skyrocketed by 2107bps to 96.69% in 2018, then decreased by -13bps to 83.78% in 2019.
  • Per Business Quant, the three most recent readings for PSTV's Gross Margin are 83.78% (Q1 2019), 96.69% (Q4 2018), and 26.81% (Q3 2018).